Medistim ASA (MEDI) Earnings Call Transcripts

Medistim ASA's Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, Medistim ASA reported record revenues exceeding NOK 200 million, reflecting an 11.1% growth year-over-year. The company achieved an EBIT of NOK 57.1 million, maintaining a strong EBIT margin of 28.3%. Management highlighted significant growth in their own product sales, particularly in the Asia Pacific region, which saw a remarkable 57.5% increase. Despite some challenges, including a decline in third-party product sales and increased operating expenses, management maintained a positive outlook for continued growth, particularly in the U.S. and Asia Pacific markets.

Reported metrics

Guidance from management

Management maintained a positive outlook for the remainder of 2026, emphasizing growth potential in the U.S. and Asia Pacific, particularly with the new direct operation in Japan and ongoing clinical trials.

What analysts pressed on

Analysts expressed concerns regarding the significant increase in operating expenses and the decline in third-party product sales. There were questions about whether the rise in costs would be a recurring issue and how the company plans to manage currency fluctuations moving forward.

Main topics on the call

• Record Revenue Achievement — Medistim surpassed NOK 200 million in revenues for the first time, achieving an 11.1% growth in NOK. Management noted, "if we adjust for currency effects, we will see that the currency-neutral sales development is actual...
• Strong Growth in Own Products — Sales of Medistim's own products increased by 28.8%, with all regions contributing positively. The Americas saw a currency-neutral growth of 30.9%, while Asia Pacific led with a 57.5% increase.
• Challenges in Third-Party Products — Third-party product sales declined by 30.2% compared to a strong prior year. Management explained that the previous year's strong sales were due to new hospital contracts, stating, "we couldn't expect that to be repeated...
• Increased Operating Expenses — Operating expenses rose significantly due to several factors, including the establishment of a direct operation in Japan and IT infrastructure upgrades. Management indicated that around NOK 5 million of the increase are ...

Read the full Medistim ASA transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 15 Medistim ASA earnings call transcripts on record, spanning October 28, 2022 to May 7, 2026. Based on this history, Medistim ASA reports quarterly. The most recent call on file is dated May 7, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MEDI

Exchange

OB

Country

NO

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

15

First call

October 28, 2022

Most recent

May 7, 2026

Reporting cadence

quarterly